You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Targeted epigenetic therapy for SCLC
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with no targeted therapeutic options and in which chemotherapy is only partially effective. Previous studies indicated that SCLC growth is suppressed by drugs that inhibit the histone lysine demethylase LSD1. Augert et al. found that LSD1 epigenetically suppressed the expression of the gene encoding NOTCH1, enabling the activity of the neuroendocrine cell lineage–associated transcription factor ASCL1. Blocking LSD1 with iadademstat (ORY-1001), a drug that has just been approved for phase 2 clinical trials in leukemia, reactivated NOTCH signaling and suppressed ASCL1 activity, inhibiting tumor growth and even inducing complete tumor regression in a patient-derived mouse model of SCLC.
This is an article distributed under the terms of the Science Journals Default License.
